Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia-Reference-Cited by-同舟云学术

Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia

Author:

Gilroy C. A.¹²^ORCID,Capozzi M. E.³^ORCID,Varanko A. K.¹,Tong J.³⁴^ORCID,D'Alessio D. A.³⁴,Campbell J. E.³⁵^ORCID,Chilkoti A.¹^ORCID

Affiliation:

1. Department of Biomedical Engineering, Duke University, Durham, NC 27708, USA.

2. Department of Nutritional Sciences and Toxicology, University of California, Berkeley, CA 94720, USA.

3. Duke Molecular Physiology Institute, Duke University, Durham, NC 27701, USA.

4. Department of Medicine, Duke University, Durham, NC 27701, USA.

5. Department of Pharmacology and Cancer Biology, Duke University, Durham, NC 27701, USA.

Abstract

A type 2 diabetes therapeutic merges two complementary drugs with a depot-forming linker to enable once-weekly dosing.

Funder

Duke MEDx

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference49 articles.

1. Centers for Disease Control and Prevention “National diabetes statistics report 2020 ” (Atlanta 2020).

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献